Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial | Zendy

Claire Higham | Zendy; A. B. Atkinson | Zendy; Simon Aylwin | Zendy; Martin Bidlingmaier | Zendy; William Drake | Zendy; A A M Lewis | Zendy; Niamh Martin | Zendy; Veronica Moyes | Zendy; John NewellPrice | Zendy; Peter Trainer | Zendy

Open Access

Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial

Author(s) -

Claire Higham,

A. B. Atkinson,

Simon Aylwin,

Martin Bidlingmaier,

William Drake,

A A M Lewis,

Niamh Martin,

Veronica Moyes,

John NewellPrice,

Peter Trainer

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2603

Subject(s) - pegvisomant , cabergoline , acromegaly , medicine , endocrinology , combination therapy , gastroenterology , urology , pharmacology , hormone , growth hormone , prolactin

With adequate dose titration, pegvisomant normalizes IGF-I in up to 97% of patients with acromegaly. Pegvisomant is indicated for treatment-resistant disease but is expensive, particularly at a high dose. It has been used successfully in combination with somatostatin analogs. However, there are no therapeutic reports of pegvisomant in combination with dopamine agonists. Cabergoline is orally active, well-tolerated, and relatively inexpensive, and as monotherapy for acromegaly it is reported to normalize IGF-I in up to 30% of patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research